GAMBARAN PENGOBATAN PERLEMAKAN HATI
NON-ALKOHOLIK PADA PASIEN DISLIPIDEMIA
DI PILOKLINIK PENYAKIT DALAM
RS PANTI RAPIH YOGYAKARTA
TAHUN 2018
Total View This Week0
Total View This Week0
Institusion
Sekolah Tinggi Ilmu Kesehatan Nasional
Author
Ajeng, Mei Rawistri
Subject
RN Pharmacy and Pharmaceutical Mathematics
Datestamp
2021-03-02 03:56:48
Abstract :
Non-alcoholic fatty liver disease (NAFLD) is a major chronic liver disease that can cause cirrhosis of the liver, liver cancer, and ultimately death. NAFLD is pathologically classified as non-alcoholic fatty liver (NAFL) or non-alcoholic steatohepatitis (NASH) based on the presence of swollen hepatocytes. Dislipidemia is a condition that often accompanies patients with non-alcoholic fatty liver. Insulin resistance, hypertriglyceridemia, hypercholesterolemia, hypertension are risk factors for non-alcoholic fatty liver. Lack of public awareness of this disease, can be dangerous if not handled properly. This research is a non observational descriptive study. The sample used was patients with internal medicine poly, data taken by 95 patients. Data is processed using descriptive analysis. The results obtained by the group of drugs that are often used in the treatment of fatty liver non-alcoholic is the Fribrats (25.3%) with the most drug use namely Fenofibrate 300mg (10 people). Other therapies include Statins (15.8%), Metformin (13.7%), Thiazolinedione (5.3%), DPP IV inhibitors (3.2%), Ezetimibe (2.1%), GLP-1 (4.2%), UDCA (14.7%), hepatoprotector supplements and vitamin E (14.7%). The characteristics of patients with comorbidities include 24 people (25.4%) with hypertension, 14 people (14.8%) diagnosed with DM, 20 people (21.1%) obese, 18 people with hyperuricemia (18.6%), dyspepsia 12 people (12.6%), with a history of Hepaptitis B 7 people (6.5%).
Non-alcoholic fatty liver disease (NAFLD) is a major chronic liver disease that can cause cirrhosis of the liver, liver cancer, and ultimately death. NAFLD is pathologically classified as non-alcoholic fatty liver (NAFL) or non-alcoholic steatohepatitis (NASH) based on the presence of swollen hepatocytes. Dislipidemia is a condition that often accompanies patients with non-alcoholic fatty liver. Insulin resistance, hypertriglyceridemia, hypercholesterolemia, hypertension are risk factors for non-alcoholic fatty liver. Lack of public awareness of this disease, can be dangerous if not handled properly. This research is a non observational descriptive study. The sample used was patients with internal medicine poly, data taken by 95 patients. Data is processed using descriptive analysis. The results obtained by the group of drugs that are often used in the treatment of fatty liver non-alcoholic is the Fribrats (25.3%) with the most drug use namely Fenofibrate 300mg (10 people). Other therapies include Statins (15.8%), Metformin (13.7%), Thiazolinedione (5.3%), DPP IV inhibitors (3.2%), Ezetimibe (2.1%), GLP-1 (4.2%), UDCA (14.7%), hepatoprotector supplements and vitamin E (14.7%). The characteristics of patients with comorbidities include 24 people (25.4%) with hypertension, 14 people (14.8%) diagnosed with DM, 20 people (21.1%) obese, 18 people with hyperuricemia (18.6%), dyspepsia 12 people (12.6%), with a history of Hepaptitis B 7 people (6.5%).
Download
book
BibTex
Latex, Jabref
cloud_download
Original Resource
url resource Institution
